MAGELLAN LONGEVITY
HomeResearchStudy library › Total plasma homocysteine level and risk of cardiovascular disease
Study summary · Cardiovascular & vascular aging

Does total plasma homocysteine level increase the risk of cardiovascular disease?

In one paragraph

Homocysteine Test, a meta-analysis (J Clin Epidemiol 2002, PMID 12393075) — the ARR for cardiac events was 1.49 (95% CI: 1.31-1.70), and for ischemic stroke, it was 1.37 (95% CI: 0.99-1.99). Age and duration of follow-up did not significantly alter these ARRs.

Source: J Clin Epidemiol 2002, PMID 12393075 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

J Clin Epidemiol · 2002 · PMID 12393075 · DOI 10.1016/s0895-4356(02)00434-1

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Higher homocysteine levels are moderately associated with an increased risk of cardiac events and ischemic stroke.

The question

Does total plasma homocysteine level increase the risk of cardiovascular disease?

What they tested

The role of homocysteine as a cardiovascular disease risk factor is controversial, with conflicting results from different study types.

How they did it

This meta-analysis synthesized data from 14 published prospective cohort studies. Average relative risks (ARRs) were calculated using fixed and random effect models. The study also assessed for publication and selection bias and the impact of individual studies on the ARR.

What they found

No evidence of publication bias (P =.62) or heterogeneity (P =.56) was found. The ARR for cardiac events was 1.49 (95% CI: 1.31-1.70), and for ischemic stroke, it was 1.37 (95% CI: 0.99-1.99). Age and duration of follow-up did not significantly alter these ARRs.

Average Relative Risk of Cardiovascular Events with Hyperhomocysteinemia
Values shown: Average Relative Risk
Cardiac Events1.49
Ischemic Stroke1.37

The average relative risk for cardiac events was 1.49, and for ischemic stroke, it was 1.37.

What it means

Hyperhomocysteinemia is associated with a moderate increase in the risk of a first cardiovascular event, independent of age and follow-up duration.

Limitations

The abstract does not explicitly state limitations of the meta-analysis itself, beyond acknowledging the prior controversy and potential for reverse causality bias in case-control studies.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Hyperhomocysteinemia moderately increases the risk of a first cardiovascular event”— from the published abstract, J Clin Epidemiol 2002

The paper at a glance

TitleTotal plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies
JournalJ Clin Epidemiol
Year2002
PMID12393075 ↗
DOI10.1016/s0895-4356(02)00434-1 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Homocysteine Test

Elevated levels predict cardiovascular mortality. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does total plasma homocysteine level increase the risk of cardiovascular disease? [Plain-English summary of J Clin Epidemiol 2002, PMID 12393075, DOI 10.1016/s0895-4356(02)00434-1]. Magellan Longevity. https://magellanlongevity.com/study/d12393075.html
BibTeX
@misc{magellan_d12393075, title = {Does total plasma homocysteine level increase the risk of cardiovascular disease?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d12393075.html}}, note = {Plain-English summary of PubMed PMID 12393075; DOI 10.1016/s0895-4356(02)00434-1; J Clin Epidemiol 2002. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d12393075.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 12393075 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.